Skip to main content
SpringerLink
Log in

Risk of Thrombosis in Cancer: Clinical Factors and Role of Primary Prophylaxis

  • Chapter
  • First Online:
Thrombosis and Hemostasis in Cancer

Part of the book series: Cancer Treatment and Research ((CTAR,volume 179))

Abstract

Cancer and its treatments are commonly complicated by venous thromboembolism (VTE), but there is a substantial variation in risk between individual cancer patients. The risk of VTE in cancer patients is influenced by multiple risk factors including primary site of cancer, stage, comorbidities, use of specific antineoplastic agents. Several biomarkers have been associated with subsequent VTE including D-dimer and tissue factor, although no single risk factor or biomarker accurately is predictive of VTE on its own. The risk of VTE is best predicted by a validated risk assessment score. Cancer patients at risk of VTE benefit from thromboprophylaxis, supported by evidence in the setting of hospitalization for acute medical illness and surgery, and emerging data from two large randomized trials in the outpatient setting. This chapter focuses on approaches to identifying risk of VTE and approaches to reducing this risk with appropriate thromboprophylaxis.

This is a preview of subscription content, log in via an institution to check access.

Access this chapter

Log in via an institution
eBook
USD 16.99
Price excludes VAT (USA)
  • Available as EPUB and PDF
  • Read on any device
  • Instant download
  • Own it forever
Softcover Book
USD 89.99
Price excludes VAT (USA)
  • Compact, lightweight edition
  • Dispatched in 3 to 5 business days
  • Free shipping worldwide - see info
Hardcover Book
USD 119.99
Price excludes VAT (USA)
  • Durable hardcover edition
  • Dispatched in 3 to 5 business days
  • Free shipping worldwide - see info

Tax calculation will be finalised at checkout

Purchases are for personal use only

Institutional subscriptions

References

  1. Khorana AA (2010) Venous thromboembolism and prognosis in cancer. Thromb Res 125(6):490–493

    Article  CAS  Google Scholar 

  2. Khorana AA, Connolly GC (2009) Assessing risk of venous thromboembolism in the patient with cancer. J Clin Oncol 27(29):4839–4847

    Article  CAS  Google Scholar 

  3. Khorana AA, Francis CW (2018, January 31) Risk prediction of cancer-associated thrombosis: appraising the first decade and developing the future. Thromb Res

    Google Scholar 

  4. Lau BD, Haut ER (2014) Practices to prevent venous thromboembolism: a brief review. BMJ Qual Saf 23(3):187–195

    Article  Google Scholar 

  5. Chew HK, Wun T, Harvey D, Zhou H, White RH (2006) Incidence of venous thromboembolism and its effect on survival among patients with common cancers. Arch Intern Med 166(4):458–464

    Article  Google Scholar 

  6. Blom JW, Doggen CJ, Osanto S, Rosendaal FR (2005) Malignancies, prothrombotic mutations, and the risk of venous thrombosis. JAMA 293(6):715–722

    Article  CAS  Google Scholar 

  7. Chew HK, Davies AM, Wun T, Harvey D, Zhou H, White RH (2008) The incidence of venous thromboembolism among patients with primary lung cancer. J Thromb Haemost 6(4):601–608

    Article  CAS  Google Scholar 

  8. Agnelli G, Bolis G, Capussotti L, Scarpa RM, Tonelli F, Bonizzoni E et al (2006) A clinical outcome-based prospective study on venous thromboembolism after cancer surgery: the @RISTOS project. Ann Surg 243(1):89–95

    Article  Google Scholar 

  9. Khorana AA, Francis CW, Culakova E, Lyman GH (2005) Risk factors for chemotherapy-associated venous thromboembolism in a prospective observational study. Cancer 104(12):2822–2829

    Article  Google Scholar 

  10. Fotopoulou C, duBois A, Karavas AN, Trappe R, Aminossadati B, Schmalfeldt B et al (2008) Incidence of venous thromboembolism in patients with ovarian cancer undergoing platinum/paclitaxel-containing first-line chemotherapy: an exploratory analysis by the Arbeitsgemeinschaft Gynaekologische Onkologie Ovarian Cancer Study Group. J Clin Oncol 26(16):2683–2689

    Article  CAS  Google Scholar 

  11. Khorana AA, Francis CW, Culakova E, Kuderer NM, Lyman GH (2007) Frequency, risk factors, and trends for venous thromboembolism among hospitalized cancer patients. Cancer 110(10):2339–2346

    Article  Google Scholar 

  12. Chen YW, Khorana AA (2017) The association between race and venous thromboembolism risk after initiation of chemotherapy: an analysis of the SAVE-ONCO trial control arm. Am J Hematol 92(6):E101–E103

    Article  Google Scholar 

  13. Starling N, Rao S, Cunningham D, Iveson T, Nicolson M, Coxon F et al (2009) Thromboembolism in patients with advanced gastroesophageal cancer treated with anthracycline, platinum, and fluoropyrimidine combination chemotherapy: a report from the UK National Cancer Research Institute Upper Gastrointestinal Clinical Studies Group. J Clin Oncol 27(23):3786–3793

    Article  CAS  Google Scholar 

  14. Scappaticci FA, Skillings JR, Holden SN, Gerber HP, Miller K, Kabbinavar F et al (2007) Arterial thromboembolic events in patients with metastatic carcinoma treated with chemotherapy and bevacizumab. J Natl Cancer Inst 99(16):1232–1239

    Article  Google Scholar 

  15. Choueiri TK, Schutz FAB, Je Y, Rosenberg JE, Bellmunt J (2010) Risk of arterial thromboembolic events with sunitinib and sorafenib: a systematic review and meta-analysis of clinical trials. JCO 28(13):2280–2285

    Article  CAS  Google Scholar 

  16. Khorana AA, Kuderer NM, Culakova E, Lyman GH, Francis CW (2008) Development and validation of a predictive model for chemotherapy-associated thrombosis. Blood 111(10):4902–4907

    Article  CAS  Google Scholar 

  17. Ay C, Vormittag R, Dunkler D et al (2009) D-dimer and prothrombin fragment 1 + 2 predict venous thromboembolism in patients with cancer: results from vienna cancer and thrombosis study. J Clin Oncol 27(25):4124–4129

    Article  CAS  Google Scholar 

  18. Angelini D, Khorana AA (2017) Risk assessment scores for cancer-associated venous thromboembolic disease. Semin Thromb Hemost 43(5):469–478

    Article  Google Scholar 

  19. Khorana AA (2018) Simplicity versus complexity: an existential dilemma as risk tools evolve. Lancet Hematol (in press)

    Google Scholar 

  20. Ay C, Dunkler D, Marosi C, Chiriac AL, Vormittag R, Simanek R et al (2010) Prediction of venous thromboembolism in cancer patients. Blood 116(24):5377–5382

    Article  CAS  Google Scholar 

  21. Verso M, Agnelli G, Barni S, Gasparini G, LaBianca R (2012) A modified Khorana risk assessment score for venous thromboembolism in cancer patients receiving chemotherapy: the Protecht score. Intern Emerg Med 7(3):291–292

    Article  Google Scholar 

  22. Cella CA, Di Minno G, Carlomagno C, Arcopinto M, Cerbone AM, Matano E et al (2017) Preventing venous thromboembolism in ambulatory cancer patients: the ONKOTEV study. Oncologist 22(5):601–608

    Article  CAS  Google Scholar 

  23. Gerotziafas GT, Taher A, Abdel-Razeq H, AboElnazar E, Spyropoulos AC, El Shemmari S et al (2017) A predictive score for thrombosis associated with breast, colorectal, lung, or ovarian cancer: the prospective COMPASS-Cancer-Associated thrombosis study. Oncologist 22(10):1222–1231

    Article  CAS  Google Scholar 

  24. Munoz Martin AJ, Ortega I, Font C, Pachon V, Castellon V, Martinez-Marin V et al (2018) Multivariable clinical-genetic risk model for predicting venous thromboembolic events in patients with cancer. Br J Cancer 118(8):1056–1061

    Article  Google Scholar 

  25. Pabinger I, Van Es N, Heinze G, Posch F, Riedl J, Reitter EM et al (2010) Development and validation of a clinical prediction model for cancer-associated venous thromboembolism in two independent prospective cohorts. Lancet Haematol

    Google Scholar 

  26. Lyman GH, Bohlke K, Khorana AA, Kuderer NM, Lee AY, Arcelus JI et al (2007) Venous thromboembolism prophylaxis and treatment in patients with cancer: American Society of clinical oncology clinical practice guideline Update 2014. JCO 33(6):654–656

    Google Scholar 

  27. Khorana AA (2007) The NCCN clinical practice guidelines on venous thromboembolic disease: strategies for improving VTE prophylaxis in hospitalized cancer patients. Oncologist 12(11):1361–1370

    Article  CAS  Google Scholar 

  28. Di Nisio MM, Carrier GH, Lyman AA (2014) Khorana and for the Subcommittee on Haemostasis and Malignancy. Prevention of venous thromboembolism in hospitalized medical cancer patients: guidance from the SSC of the ISTH. J Throm Haemost 12:1746–1749

    Google Scholar 

  29. Samama MM, Cohen AT, Darmon J, Desjardins L, Eldor A, Janbon C et al (1999) A comparison of enoxaparin with placebo for the prevention of venous thromboembolism in acutely ill medical patients. N Engl J Med 341(11):793–800

    Article  CAS  Google Scholar 

  30. Agnelli G, George DJ, Kakkar AK, Fisher W, Lassen MR, Mismetti P et al (2012) Semuloparin for thromboprophylaxis in patients receiving chemotherapy for cancer. N Engl J Med 366(7):601–609

    Article  CAS  Google Scholar 

  31. Hogg K, Carrier M (2012) Prevention and treatment of venous thromboembolism in patients with cancer. Therapeutic Adv Hematol 3(1):45–58

    Article  CAS  Google Scholar 

  32. Khorana AA, Francis CW, Kuderer NM, Carrier M, Ortel TL, Wun T et al (2017) Dalteparin thromboprophylaxis in cancer patients at high risk for venous thromboembolism: a randomized trial. Thromb Res 151:89–95

    Article  CAS  Google Scholar 

  33. Khorana AA, Soff GA, Kakkar AK, Vadhan-Raj S, Riess H, Wun T et al (2018) Rivaroxaban thromboprophylaxis in high-risk ambulatory cancer patients receiving systemic therapy: results of a randomized clinical trial (CASSINI). Blood 132(Suppl 1). LBA-1. Accessed December 27, 2018. https://doi.org/10.1182/blood-2018-120738

  34. Carrier M, Abou-Nassar K, Mallick R, Tagalakis V, Shivakumar S, Schattner A, Kuruvilla P, Hill D, Spadafora S, Marquis K, Trinkaus M (2018) Apixaban to prevent venous thromboembolism in patients with cancer. New England J Med

    Google Scholar 

  35. Levine MN, Gu C, Liebman HA, Escalante CP, Solymoss S, Deitchman D et al (2012) A randomized phase II trial of apixaban for the prevention of thromboembolism in patients with metastatic cancer. J Thromb Haemost 10(5):807–814

    Article  CAS  Google Scholar 

  36. Akl EA, Kamath G, Yosuico V, Kim SY, Barba M, Sperati F et al (2008) Thromboprophylaxis for patients with cancer and central venous catheters: a systematic review and a meta-analysis. Cancer 112(11):2483–2492

    Article  CAS  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Taussig Cancer Institute Cleveland Clinic, 10201 Carnegie Ave, CA60, Cleveland, OH, 44195, USA

    Joanna Roopkumar & Alok A. Khorana

Authors
  1. Joanna Roopkumar
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Alok A. Khorana
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Alok A. Khorana .

Editor information

Editors and Affiliations

  1. Medicine/Hematology, Memorial Sloan Kettering Cancer Center, New York, NY, USA

    Gerald Soff

Rights and permissions

Reprints and permissions

Copyright information

© 2019 Springer Nature Switzerland AG

About this chapter

Check for updates. Verify currency and authenticity via CrossMark

Cite this chapter

Roopkumar, J., Khorana, A.A. (2019). Risk of Thrombosis in Cancer: Clinical Factors and Role of Primary Prophylaxis. In: Soff, G. (eds) Thrombosis and Hemostasis in Cancer. Cancer Treatment and Research, vol 179. Springer, Cham. https://doi.org/10.1007/978-3-030-20315-3_4

Download citation

  • DOI: https://doi.org/10.1007/978-3-030-20315-3_4

  • Published:

  • Publisher Name: Springer, Cham

  • Print ISBN: 978-3-030-20314-6

  • Online ISBN: 978-3-030-20315-3

  • eBook Packages: MedicineMedicine (R0)

Publish with us

Policies and ethics

Search

Navigation